{
  "schema": "https://miscsubjects.com/schemas/jarticle.json",
  "status": "published",
  "slug": "retatrutide-glp1-agonists",
  "title": "retatrutide glp1 agonists",
  "kind": "standard",
  "summary": "Evidence is being populated by Grok web",
  "created": "2026-06-29T17:43:32.319Z",
  "body": [
    "## Overview\nEvidence is being populated by Grok web search."
  ],
  "facts": {
    "converted_from": "markdown",
    "original_updated": "2026-06-29T17:43:51.697Z",
    "register": "standard",
    "category": null
  },
  "sources": [
    {
      "id": "s1",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41723268/",
      "title": "Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...",
      "quote": "Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.",
      "summary": "2026 study showing anti-obesity effects of retatrutide and comparators in MC4R KO mice.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:32.443Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "genesis",
      "hash": "d1683ea5935261c4b3e540e35123846d998a2f0c0c6857a20ee1f48c1f92ef75",
      "quote_sha256": "4445cb67296f9791c652316100989230509e9130a60aefdcc9c2b6632ff8267f"
    },
    {
      "id": "s2",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40685589/",
      "title": "Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...",
      "quote": "Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.",
      "summary": "2025/2026 comparison of GLP-1 agonists including retatrutide on efficacy and safety.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:32.443Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "d1683ea5935261c4b3e540e35123846d998a2f0c0c6857a20ee1f48c1f92ef75",
      "hash": "91c54969fdb55658795ce6925aa0bf2ae4027f4b45d44462629ce8bb170f90dc",
      "quote_sha256": "bdda6c0cc48f48acd43101c16044bd88096b157ce8bb8bc305c471233ae3e3dc"
    },
    {
      "id": "s3",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40291085/",
      "title": "Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...",
      "quote": "Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.",
      "summary": "Meta or review on retatrutide's effects in obesity.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:32.443Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "91c54969fdb55658795ce6925aa0bf2ae4027f4b45d44462629ce8bb170f90dc",
      "hash": "d09058577dab1f1a5637fdc7e29607acc03e770cbb22bce0592ec02b2683a707",
      "quote_sha256": "9626f94ca6280fc9bae93b3f39e6ba1fbb89914baa861895b1c0a60affc8e159"
    },
    {
      "id": "s4",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40563436/",
      "title": "Retatrutide-A Game Changer in Obesity Pharmacotherapy",
      "quote": "Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...",
      "summary": "2025 review highlighting retatrutide as triple agonist for obesity and T2DM.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:32.443Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "d09058577dab1f1a5637fdc7e29607acc03e770cbb22bce0592ec02b2683a707",
      "hash": "d6970f615871708696a0f4b689dfe2e2a22e19a67f6608b3d4909e70083e8318",
      "quote_sha256": "ea5d1195a7e1761906d11be1522a4f14ded9f5761270a5c78bda69a0eefd827c"
    },
    {
      "id": "s5",
      "type": "clinical_trial",
      "url": "https://clinicaltrials.gov/study/NCT05882045",
      "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)",
      "quote": "The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).",
      "summary": "Ongoing phase 3 trial on retatrutide for obesity with CVD.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:32.443Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "d6970f615871708696a0f4b689dfe2e2a22e19a67f6608b3d4909e70083e8318",
      "hash": "71b2363f74d8cdb08d52eabe603f162d7ac5b04e990aab785ebd502c2ed9598a",
      "quote_sha256": "710e155420c839f731b51306f848642c31eff884fc81b88d741b73d676deae0f"
    },
    {
      "id": "s6",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42250575/",
      "title": "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)",
      "quote": "Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.",
      "summary": "2026 phase 3 trial results in T2D patients.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:32.443Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "71b2363f74d8cdb08d52eabe603f162d7ac5b04e990aab785ebd502c2ed9598a",
      "hash": "07fd561d3e724bd7289bd9fc8c9ba65b293ebc3aaafd5e25aa0b08f276df9bb6",
      "quote_sha256": "15565542487d294b5989b6e3582dc50e20419e57ec5bdc7476017bd465d9a6eb"
    },
    {
      "id": "s7",
      "type": "review",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41785010/",
      "title": "Retatrutide in type 2 diabetes mellitus and obesity: an overview",
      "quote": "Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).",
      "summary": "2026 review on retatrutide for T2DM and obesity, noting significant weight loss up to 16.94% in T2DM subjects.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "07fd561d3e724bd7289bd9fc8c9ba65b293ebc3aaafd5e25aa0b08f276df9bb6",
      "hash": "0413b2dceecc121c9344f2393b120dc7bd4fa130f2536018d65985efa23a0638",
      "quote_sha256": "2925e1c548e478ba32a52fc9530a73b9962977cbbd8b7a971f7e63603f245ad6"
    },
    {
      "id": "s8",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41545327/",
      "title": "Retatrutide and the Paradigm Shift in Multi-Hormonal ...",
      "quote": "Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.",
      "summary": "2026 PubMed article on retatrutide as a triple agonist for obesity treatment.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "0413b2dceecc121c9344f2393b120dc7bd4fa130f2536018d65985efa23a0638",
      "hash": "520b95b711b028b7bba17be154a2028bcbb775dbad63438aa8b1382346687c4a",
      "quote_sha256": "201f72b0c9789835304266dcc6c478a9134ac46e3c992f24eb203ff7fa8c325f"
    },
    {
      "id": "s9",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42135195/",
      "title": "Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes",
      "quote": "retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.",
      "summary": "2026 study on retatrutide's effects on lipids and metabolites in obesity/T2D.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "520b95b711b028b7bba17be154a2028bcbb775dbad63438aa8b1382346687c4a",
      "hash": "1192147733cc9b9d62d25d617cee59c3c9654dd609e3b3714b1644fead9b822c",
      "quote_sha256": "4b80eb58b052d9d92eeefe889d21259264d9a8804907dc56920b1f7439d8618a"
    },
    {
      "id": "s10",
      "type": "review",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42108533/",
      "title": "Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review",
      "quote": "Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.",
      "summary": "2026 comprehensive review on retatrutide for CKM syndrome, including liver disease benefits.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "1192147733cc9b9d62d25d617cee59c3c9654dd609e3b3714b1644fead9b822c",
      "hash": "be593910255a4e73aa5237dc56b68903b46dea4c7877f8444343861e8b80a3fb",
      "quote_sha256": "ac66fd9f6fd80119c5231554f0e9e1887fc9af5e5abbbe157ca469084d0f680d"
    },
    {
      "id": "s11",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41741376/",
      "title": "Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models",
      "quote": "Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.",
      "summary": "2026 preclinical study on metabolic benefits of retatrutide in MASH models.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "be593910255a4e73aa5237dc56b68903b46dea4c7877f8444343861e8b80a3fb",
      "hash": "b61d2944fb0e25dd65626d2748f78786b7b07a05bcd52bf90dfcef892ca3d37e",
      "quote_sha256": "b9440ea6da449ffb441ca5236a37aeb1a31d3d65e4b5f063907936a65b3721d9"
    },
    {
      "id": "s12",
      "type": "clinical_trial",
      "url": "https://clinicaltrials.gov/study/NCT07232719",
      "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)",
      "quote": "The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.",
      "summary": "New 2026 Phase 3 trial NCT07232719 for retatrutide in obesity/overweight.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "b61d2944fb0e25dd65626d2748f78786b7b07a05bcd52bf90dfcef892ca3d37e",
      "hash": "40117b02abb718facc077b7e51c3e1660ac4fe195db35a0ca87e1b635f2a215f",
      "quote_sha256": "be6e6d2a4ec6b8a4fd11f1a115b93bdda8fd20fda6bb19f958af6adbd09e2fb1"
    },
    {
      "id": "s13",
      "type": "clinical_trial",
      "url": "https://clinicaltrials.gov/study/NCT06662383",
      "title": "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)",
      "quote": "The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.",
      "summary": "New Phase 3 trial comparing retatrutide to tirzepatide in obesity.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:43:51.054Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "40117b02abb718facc077b7e51c3e1660ac4fe195db35a0ca87e1b635f2a215f",
      "hash": "1a0ff0178209f4d93e297f0e32fcf31038b10a0ae6c312c65bbe05f8fa3313e5",
      "quote_sha256": "510618aca961ab8d918c0ef7ad5c7d8e009cc05a4341cda400856ffdf51a49b8"
    }
  ],
  "type": "article",
  "updated": "2026-10-08T11:49:31.891Z",
  "version": 1,
  "hash": "3ecbb35fa719d711e036669b9887d02c985648c3ddea9a7f9921743cdc1f9356",
  "styling": {
    "scope": "shared",
    "how": "no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
    "widget_style": {
      "what": "every widget may carry style: {…}; these are the only keys it reads",
      "rotate": "degrees, a number",
      "offset_x": "pixels, a number",
      "offset_y": "pixels, a number",
      "pulse": "true to pulse"
    },
    "theme": {
      "color": {
        "page_bg": "#f5f5f7",
        "sheet_bg": "#ffffff",
        "ink": "#1d1d1f",
        "soft": "#424245",
        "muted": "#6e6e73",
        "dim": "#86868b",
        "line": "#d2d2d7",
        "accent": "#0071e3",
        "accent_soft": "rgba(0,113,227,0.08)",
        "link": "#0066cc",
        "selection": "rgba(0,113,227,0.18)",
        "widget_bg": "#f5f5f7",
        "widget_border": "#d2d2d7",
        "card_bg": "#ffffff",
        "code_bg": "#f5f5f7",
        "json_bg": "#161b19",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#928d7e",
        "json_punct": "#6b6759",
        "json_bar": "#0e1512",
        "kind_badge_bg": "#0e6e60",
        "kind_badge_ink": "#ffffff"
      },
      "color_dark": {
        "page_bg": "#000000",
        "sheet_bg": "#1d1d1f",
        "ink": "#f5f5f7",
        "soft": "#d2d2d7",
        "muted": "#a1a1a6",
        "dim": "#86868b",
        "line": "#424245",
        "accent": "#2997ff",
        "accent_soft": "rgba(41,151,255,0.12)",
        "link": "#2997ff",
        "selection": "rgba(41,151,255,0.25)",
        "widget_bg": "#2c2c2e",
        "widget_border": "#424245",
        "card_bg": "#1d1d1f",
        "code_bg": "#2c2c2e",
        "json_bg": "#0a0d0c",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#757062",
        "json_punct": "#5d665f",
        "json_bar": "#060807",
        "kind_badge_bg": "#4fc1ab",
        "kind_badge_ink": "#0b0f0d"
      },
      "font": {
        "display": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "body": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "mono": "ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
        "google_fonts": ""
      },
      "size": {
        "body": "17px",
        "small": "17px",
        "eye": "17px",
        "lead": "17px",
        "h1": "52px",
        "h2": "34px",
        "h3": "22px",
        "byline": "17px",
        "h1_measure": "none",
        "code": "17px",
        "json": "17px",
        "widget_title": "17px"
      },
      "leading": {
        "body": "1.7",
        "head": "1.18",
        "lead": "1.5",
        "json": "1.6"
      },
      "weight": {
        "display": "700",
        "head": "700",
        "body": "400",
        "strong": "700",
        "eye": "700"
      },
      "tracking": {
        "eye": "0.14em",
        "display": "-0.03em",
        "body": "-0.006em",
        "badge": "0.08em"
      },
      "layout": {
        "sheet_width": "1000px",
        "text_width": "880px",
        "gutter": "16px",
        "sheet_padding": "56px 64px 64px",
        "sheet_padding_mobile": "24px 18px 40px",
        "sheet_margin": "28px auto 72px",
        "block_gap": "1.15em",
        "widget_gap": "28px",
        "grid_gap": "14px"
      },
      "border": {
        "sheet": "0px solid",
        "sheet_radius": "30px",
        "widget": "1px solid",
        "widget_radius": "24px",
        "card_radius": "24px",
        "badge_radius": "999px",
        "rule": "1px solid",
        "code_radius": "18px",
        "accent_bar": "3px"
      },
      "shadow": {
        "sheet": "0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
        "widget": "none",
        "card_hover": "0 10px 28px -16px rgba(28,27,23,0.35)"
      },
      "motion": {
        "hover": "160ms ease"
      }
    }
  },
  "page": "https://miscsubjects.com/a/retatrutide-glp1-agonists",
  "json": "https://miscsubjects.com/a/retatrutide-glp1-agonists.json",
  "markdown": "https://miscsubjects.com/a/retatrutide-glp1-agonists.md",
  "theme": "https://miscsubjects.com/article-theme.json",
  "calls": [
    {
      "what": "this article as a page (no key)",
      "method": "GET",
      "url": "https://miscsubjects.com/a/retatrutide-glp1-agonists",
      "headers": {}
    },
    {
      "what": "this article as its object (no key)",
      "method": "GET",
      "url": "https://miscsubjects.com/a/retatrutide-glp1-agonists.json",
      "headers": {}
    },
    {
      "what": "this article as Markdown (no key)",
      "method": "GET",
      "url": "https://miscsubjects.com/a/retatrutide-glp1-agonists.md",
      "headers": {}
    },
    {
      "what": "the object with its hash, drafts too",
      "method": "GET",
      "url": "https://miscsubjects.com/api/jarticles/retatrutide-glp1-agonists",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "one piece and that piece’s hash",
      "method": "GET",
      "url": "https://miscsubjects.com/api/jarticles/retatrutide-glp1-agonists/at?path=facts",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "grep: every key or value that matches, with the path to change it",
      "method": "GET",
      "url": "https://miscsubjects.com/api/jarticles/retatrutide-glp1-agonists/grep?q=owner",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "change pieces (set, merge, delete, append, insert, move); if-match is the hash",
      "method": "PATCH",
      "url": "https://miscsubjects.com/api/jarticles/retatrutide-glp1-agonists",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash from the read>"
      },
      "body": {
        "ops": [
          {
            "op": "set",
            "path": "facts.example",
            "value": 1
          }
        ]
      }
    },
    {
      "what": "replace the whole object",
      "method": "PUT",
      "url": "https://miscsubjects.com/api/jarticles/retatrutide-glp1-agonists",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash>"
      },
      "body": {
        "slug": "retatrutide-glp1-agonists",
        "title": "…"
      }
    },
    {
      "what": "fetch every source, hash what came back and check the quote is in it",
      "method": "POST",
      "url": "https://miscsubjects.com/api/jarticles/retatrutide-glp1-agonists/verify",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {}
    },
    {
      "what": "an Obsidian-style command",
      "method": "POST",
      "url": "https://miscsubjects.com/api/jarticles/cli",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {
        "command": "backlinks",
        "file": "retatrutide-glp1-agonists"
      }
    }
  ]
}